#CTAD26
Among former football players with autopsy data, plasma endogenously cleaved microtubule-binding region tau was higher in high-stage #ChronicTraumaticEncephalopathy than in low-stage or no CTE. #CTAD26 ja.ma/3UN7wUx
Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology
This case series investigates whether plasma endogenously cleaved microtubule-binding region tau (eMTBR-tau) can serve as an in vivo biomarker of chronic traumatic encephalopathy tau tangle neuropathology.
ja.ma
November 19, 2026 at 9:30 PM
💬 Editorial: Plasma endogenously cleaved microtubule-binding region tau is a promising candidate biomarker for #ChronicTraumaticEncephalopathy, but larger studies are needed to establish diagnostic accuracy and specificity. #CTAD26 ja.ma/4l7DSDU
Plasma eMTBR-Tau as a Potential Biomarker Across Tauopathies
Chronic traumatic encephalopathy (CTE) remains a major diagnostic challenge because its defining neuropathologic changes can be confirmed only at postmortem examination. Although use of clinical criteria, neuroimaging, and currently available fluid biomarkers can provide useful information, a...
ja.ma
November 19, 2026 at 9:30 PM
Can improving heart health improve brain health? New results from the Alzheimer's Association U.S. POINTER Study say yes. www.alz.org/news/2026/al... #CTAD26
November 18, 2026 at 7:26 PM
Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s, according to data at #CTAD26. The company hasn't said much about the pill, but it was one of its efforts to branch out beyond amyloid antibodies. My story for @endpts.com has the details: endpoints.news/ctad26-lilly...
Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s
Lilly's mevidalen failed Phase 2 in Alzheimer's patients, missing iADRS improvement goals. No further development planned for the dopamine D1 receptor drug.
endpoints.news
November 18, 2026 at 4:27 PM
Watching Biogen $BIIB: diranersen MAPT ASO lowers CSF p-tau, 38% CDR-SB at 2y. Mechanisitc rescue; lens refocussed, market mispriced-call +45% rerate. https://endpoints.news/ctad26-biogens-tau-drug-slows-alzheimers-more-after-nearly-two-years/
November 18, 2026 at 5:03 PM
Biogen’s tau-silencing drug diranersen slows Alzheimer’s by 38% after nearly two years, up from 26% slowing after 18 months, according to data at #CTAD26. But lots of caveats, including a small group and imperfect placebo comparison. Details in @endpts.com - endpoints.news/ctad26-bioge...
Biogen says low dose of its experimental tau-reducing drug fares even better after nearly 2 years
Biogen's diranersen slowed Alzheimer's progression 38% after ~2 years vs 26% at 18 months, per data at CTAD Boston. Phase 3 trial planned.
endpoints.news
November 18, 2026 at 1:15 AM
Cognito plans FDA submission of light and sound therapy for Alzheimer’s despite missing its primary endpoint in both the overall population and mild disease subgroup. Data of pivotal study presented at #CTAD26. My story for @endpts.com has the details: endpoints.news/ctad26-cogni...
Despite trial miss, Cognito readies Alzheimer’s light and sound headset for FDA
Cognito Therapeutics' Spectris device showed mixed Alzheimer's results; failed primary endpoints but slowed decline 56% in mild-stage patients. FDA submission planned Q2 2026.
endpoints.news
November 17, 2026 at 4:51 PM
Lilly's dopamine drug mevidalen failed a Phase 2 study in Alzheimer's, and the pharma has ended the program. #CTAD26
Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s
Lilly's mevidalen failed Phase 2 in Alzheimer's patients, missing iADRS improvement goals. No further development planned for the dopamine D1 receptor drug.
endpoints.news
November 18, 2026 at 8:02 PM
Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. #CTAD26
https://www.medpagetoday.com/meetingcoverage/ctad/123956
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
Open-label extension data suggest diranersen's treatment effects may build over time
www.medpagetoday.com
November 19, 2026 at 1:05 AM
Mirodenafil (known as AR1001), an oral phosphodiesterase-5 inhibitor approved in South Korea to treat erectile dysfunction, showed mixed results in people with early Alzheimer's disease in the phase III POLARIS-AD trial. #CTAD26
https://www.medpagetoday.com/meetingcoverage/ctad/123938
Erectile Dysfunction Drug Shows Mixed Results in Alzheimer's
AR1001 missed the primary endpoint in one population, but slowed decline in another
www.medpagetoday.com
November 18, 2026 at 6:32 PM
For nearly a decade, the German biotech Priavoid has been working on a pill to break up small clumps of amyloid proteins. In a 300-person study presented at #CTAD26 this morning, the drug failed to slow Alzheimer's disease. More details in @endpts.com: endpoints.news/priavoids-am...
Priavoid’s amyloid-detangling pill fails to meaningfully slow disease in Phase 2 Alzheimer’s study
Priavoid’s oral amyloid oligomer drug PRI-002 misses primary endpoint in 300-person Ph2 Alzheimer’s study; next steps undecided.
endpoints.news
November 17, 2026 at 3:35 PM
Despite a trial miss, Cognito plans to seek FDA authorization for its light and sound Alzheimer's headset next year. #CTAD26
Despite trial miss, Cognito readies Alzheimer’s light and sound headset for FDA
Cognito Therapeutics' Spectris device showed mixed Alzheimer's results; failed primary endpoints but slowed decline 56% in mild-stage patients. FDA submission planned Q2 2026.
endpoints.news
November 17, 2026 at 8:21 PM